圣湘生物董事长创立核聚变公司？公司回应来了

Core Viewpoint - The establishment of Honghu Fusion by Dai Lizhong, the chairman of Shengxiang Bio, is a personal investment and does not involve the daily operations of the company [1][2]. Company Overview - Shengxiang Bio focuses on innovative gene technology and provides integrated diagnostic solutions, including in vitro diagnostic reagents, instruments, third-party medical testing services, and biopharmaceuticals [3]. - In the first half of 2025, Shengxiang Bio achieved revenue of 869 million yuan, a year-on-year increase of 21.15%, and a net profit attributable to shareholders of 163 million yuan, up 3.84% [3]. Investment in Fusion Energy - Honghu Fusion, founded in 2023, is a commercial fusion enterprise specializing in high-temperature superconducting stellarator technology, which is seen as a strategic area in global energy technology competition [2]. - The company has established a deep collaboration with Shanghai Jiao Tong University for laboratory co-construction, technology research and development, and talent cultivation [2]. - Dai Lizhong has been advocating for the integration of national and market resources to promote the commercialization of fusion energy for several years [4].